0.07
+0.00005(+0.07%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.07 |
| Day High | 0.07 |
| Day Low | 0.07 |
| 52-Week High | 3.39 |
| 52-Week Low | 0.05 |
| Volume | 218 |
| Average Volume | 72,644 |
| Market Cap | 569,506 |
| PE | -0.11 |
| EPS | -0.64 |
| Moving Average 50 Days | 0.12 |
| Moving Average 200 Days | 0.32 |
| Change | 0 |
If you invested $1000 in Bio-Path Holdings, Inc. (BPTH) 10 years ago, it would be worth $0.02 as of September 29, 2025 at a share price of $0.069. Whereas If you bought $1000 worth of Bio-Path Holdings, Inc. (BPTH) shares 5 years ago, it would be worth $0.79 as of September 29, 2025 at a share price of $0.069.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
GlobeNewswire Inc.
Jun 09, 2025 11:00 AM GMT
HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obe
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Newsfile
Jun 04, 2025 8:34 PM GMT
Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage b
Bio-Path Holdings Provides Clinical and Operational Update
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNA